Vice President TCG Labs Soleil South San Francisco, California, United States
This presentation will focus on novel antibody-based therapeutics (e.g. antibody fragments, intrabodies, nanobodies) that are being developed to cross the blood brain barrier for the treatment of neurologic or neuromuscular diseases. The discussion will include mechanism of action, approaches for in-vitro and in-vivo characterization as well as pathology considerations unique to the safety assessment of these novel brain-targeted modalities.
